Review



tim3  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems tim3
    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Tim3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3/product/R&D Systems
    Average 94 stars, based on 6 article reviews
    tim3 - by Bioz Stars, 2026-04
    94/100 stars

    Images

    1) Product Images from "Single-Cell Profiling Reveals Developmental Trajectories and identifies SYK and TIM3 as Targets in some T Cell Lymphomas"

    Article Title: Single-Cell Profiling Reveals Developmental Trajectories and identifies SYK and TIM3 as Targets in some T Cell Lymphomas

    Journal: bioRxiv

    doi: 10.64898/2026.03.27.714741

    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, TIM3+ T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Figure Legend Snippet: (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, TIM3+ T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.

    Techniques Used: Staining, Expressing



    Similar Products

    94
    Miltenyi Biotec anti human tim3 f38 2e2
    Anti Human Tim3 F38 2e2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human tim3 f38 2e2/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    anti human tim3 f38 2e2 - by Bioz Stars, 2026-04
    94/100 stars
      Buy from Supplier

    92
    Cytek Biosciences pe anti tim3
    Pe Anti Tim3, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe anti tim3/product/Cytek Biosciences
    Average 92 stars, based on 1 article reviews
    pe anti tim3 - by Bioz Stars, 2026-04
    92/100 stars
      Buy from Supplier

    94
    R&D Systems tim3
    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Tim3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    tim3 - by Bioz Stars, 2026-04
    94/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec tim3 apc
    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Tim3 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3 apc/product/Miltenyi Biotec
    Average 95 stars, based on 1 article reviews
    tim3 apc - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    95
    Bio X Cell anti mouse tim3
    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Anti Mouse Tim3, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse tim3/product/Bio X Cell
    Average 95 stars, based on 1 article reviews
    anti mouse tim3 - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    95
    ACROBiosystems human tim3
    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Human Tim3, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human tim3/product/ACROBiosystems
    Average 95 stars, based on 1 article reviews
    human tim3 - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    95
    Proteintech anti tim3 antibody
    Compound 053 modulates co-stimulatory and co-inhibitory molecules on T cell surfaces. (A) The protein levels of 4-1BB, OX40 and CD40L after 5 μ M ADM, GEM (80 μ M), 053 (5 μ M) or CQ (30 μ M) treatment were analyzed by western blotting. (B) The protein levels of <t>TIM3,</t> PD-1 and VISTA after 5 μ M ADM, GEM (80 μ M), 053 (5 μ M) or CQ (30 μ M) treatment were analyzed by western blotting. (C) After T cells were treated with 053 (0-10 μ M) for 24 h, ICOS expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (D) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of ICOS expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (E) After T cells were treated with 053 (0-10 μ M) for 24 h, OX-40 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (F) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of OX-40 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (G) After T cells were treated with 053 (0-10 μ M) for 24 h, 4-1BB expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (H) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of 4-1BB expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (I) After T cells were treated with 053 (0-10 μ M) for 24 h, TIM3 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (J) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of TIM3 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (K) After T cells were treated with 053 (0-10 μ M) for 24 h, PD-1 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (L) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of PD-1 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. Data are presented as mean ± SEM (n=3). Statistical significance was determined by one-way ANOVA followed by Dunnett's multiple comparisons test to compare all experimental groups against a single control group. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 vs. 0 μ M 053. 053, FZU-0045-053; ADM, adriamycin; 4-1BB, tumor necrosis factor receptor superfamily member 9; OX40, tumor necrosis factor receptor superfamily member 4; CD40L, CD40 ligand; ICOS, inducible T-cell co-stimulator; PD-1, programmed cell death protein 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3; VISTA, V-domain Ig suppressor of T cell activation; GEM, gemcitabine; CQ, chloroquine.
    Anti Tim3 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti tim3 antibody/product/Proteintech
    Average 95 stars, based on 1 article reviews
    anti tim3 antibody - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    85
    R&D Systems human tim3 biotinylated antibody
    Compound 053 modulates co-stimulatory and co-inhibitory molecules on T cell surfaces. (A) The protein levels of 4-1BB, OX40 and CD40L after 5 μ M ADM, GEM (80 μ M), 053 (5 μ M) or CQ (30 μ M) treatment were analyzed by western blotting. (B) The protein levels of <t>TIM3,</t> PD-1 and VISTA after 5 μ M ADM, GEM (80 μ M), 053 (5 μ M) or CQ (30 μ M) treatment were analyzed by western blotting. (C) After T cells were treated with 053 (0-10 μ M) for 24 h, ICOS expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (D) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of ICOS expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (E) After T cells were treated with 053 (0-10 μ M) for 24 h, OX-40 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (F) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of OX-40 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (G) After T cells were treated with 053 (0-10 μ M) for 24 h, 4-1BB expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (H) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of 4-1BB expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (I) After T cells were treated with 053 (0-10 μ M) for 24 h, TIM3 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (J) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of TIM3 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (K) After T cells were treated with 053 (0-10 μ M) for 24 h, PD-1 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (L) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of PD-1 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. Data are presented as mean ± SEM (n=3). Statistical significance was determined by one-way ANOVA followed by Dunnett's multiple comparisons test to compare all experimental groups against a single control group. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 vs. 0 μ M 053. 053, FZU-0045-053; ADM, adriamycin; 4-1BB, tumor necrosis factor receptor superfamily member 9; OX40, tumor necrosis factor receptor superfamily member 4; CD40L, CD40 ligand; ICOS, inducible T-cell co-stimulator; PD-1, programmed cell death protein 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3; VISTA, V-domain Ig suppressor of T cell activation; GEM, gemcitabine; CQ, chloroquine.
    Human Tim3 Biotinylated Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human tim3 biotinylated antibody/product/R&D Systems
    Average 85 stars, based on 1 article reviews
    human tim3 biotinylated antibody - by Bioz Stars, 2026-04
    85/100 stars
      Buy from Supplier

    Image Search Results


    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, TIM3+ T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.

    Journal: bioRxiv

    Article Title: Single-Cell Profiling Reveals Developmental Trajectories and identifies SYK and TIM3 as Targets in some T Cell Lymphomas

    doi: 10.64898/2026.03.27.714741

    Figure Lengend Snippet: (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, TIM3+ T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.

    Article Snippet: Following heat-mediated antigen retrieval, consecutive sections were stained for TIM3 (MAB23652, R&D Systems) and CD30 (M0751, Agilent Dako) both at a 1:50 dilution.

    Techniques: Staining, Expressing

    Compound 053 modulates co-stimulatory and co-inhibitory molecules on T cell surfaces. (A) The protein levels of 4-1BB, OX40 and CD40L after 5 μ M ADM, GEM (80 μ M), 053 (5 μ M) or CQ (30 μ M) treatment were analyzed by western blotting. (B) The protein levels of TIM3, PD-1 and VISTA after 5 μ M ADM, GEM (80 μ M), 053 (5 μ M) or CQ (30 μ M) treatment were analyzed by western blotting. (C) After T cells were treated with 053 (0-10 μ M) for 24 h, ICOS expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (D) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of ICOS expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (E) After T cells were treated with 053 (0-10 μ M) for 24 h, OX-40 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (F) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of OX-40 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (G) After T cells were treated with 053 (0-10 μ M) for 24 h, 4-1BB expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (H) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of 4-1BB expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (I) After T cells were treated with 053 (0-10 μ M) for 24 h, TIM3 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (J) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of TIM3 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (K) After T cells were treated with 053 (0-10 μ M) for 24 h, PD-1 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (L) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of PD-1 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. Data are presented as mean ± SEM (n=3). Statistical significance was determined by one-way ANOVA followed by Dunnett's multiple comparisons test to compare all experimental groups against a single control group. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 vs. 0 μ M 053. 053, FZU-0045-053; ADM, adriamycin; 4-1BB, tumor necrosis factor receptor superfamily member 9; OX40, tumor necrosis factor receptor superfamily member 4; CD40L, CD40 ligand; ICOS, inducible T-cell co-stimulator; PD-1, programmed cell death protein 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3; VISTA, V-domain Ig suppressor of T cell activation; GEM, gemcitabine; CQ, chloroquine.

    Journal: International Journal of Oncology

    Article Title: Discovery of the late autophagy inhibitor FZU-0045-053 and its anti-breast cancer and immunomodulatory effects

    doi: 10.3892/ijo.2025.5823

    Figure Lengend Snippet: Compound 053 modulates co-stimulatory and co-inhibitory molecules on T cell surfaces. (A) The protein levels of 4-1BB, OX40 and CD40L after 5 μ M ADM, GEM (80 μ M), 053 (5 μ M) or CQ (30 μ M) treatment were analyzed by western blotting. (B) The protein levels of TIM3, PD-1 and VISTA after 5 μ M ADM, GEM (80 μ M), 053 (5 μ M) or CQ (30 μ M) treatment were analyzed by western blotting. (C) After T cells were treated with 053 (0-10 μ M) for 24 h, ICOS expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (D) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of ICOS expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (E) After T cells were treated with 053 (0-10 μ M) for 24 h, OX-40 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (F) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of OX-40 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (G) After T cells were treated with 053 (0-10 μ M) for 24 h, 4-1BB expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (H) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of 4-1BB expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (I) After T cells were treated with 053 (0-10 μ M) for 24 h, TIM3 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (J) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of TIM3 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. (K) After T cells were treated with 053 (0-10 μ M) for 24 h, PD-1 expression on T cell surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (L) T cells were co-cultured with MDA-MB-231 cells at a 1:1 ratio and treated with 053 (0-10 μ M) for 24 h, followed by flow cytometric analysis of PD-1 expression on T cell surfaces. The bar graph shows quantitative analysis of relative fluorescence intensity. Data are presented as mean ± SEM (n=3). Statistical significance was determined by one-way ANOVA followed by Dunnett's multiple comparisons test to compare all experimental groups against a single control group. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 vs. 0 μ M 053. 053, FZU-0045-053; ADM, adriamycin; 4-1BB, tumor necrosis factor receptor superfamily member 9; OX40, tumor necrosis factor receptor superfamily member 4; CD40L, CD40 ligand; ICOS, inducible T-cell co-stimulator; PD-1, programmed cell death protein 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3; VISTA, V-domain Ig suppressor of T cell activation; GEM, gemcitabine; CQ, chloroquine.

    Article Snippet: The sections were then blocked with 5% BSA for 1 h at room temperature and subsequently incubated overnight at 4°C with the following primary antibodies: Anti-Ki67 antibody (cat. no. GB111499-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-LC3 antibody (cat. no. 81004-1-RR; 1:1,000; Proteintech Group, Inc), anti-p62 antibody (cat. no. GB11239-1-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-PD-L1 antibody (cat. no. GB150059-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-PD-L2 antibody (cat. no. 27406-1-AP; 1:4,000; Proteintech Group, Inc), anti-CD3 antibody (cat. no. GB11014-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-CD4 antibody (cat. no. GB11064-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-CD8 antibody (cat. no. GB11068; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-4-1BB/CD137 antibody (cat. no. A2025; 1:200; ABclonal Biotech Co., Ltd), anti-CD134/OX40 antibody (cat. no. 32621-1-AP; 1:500; Proteintech Group, Inc), anti-PD1 antibody (cat. no. GB153744-100; 1:400; Wuhan Servicebio Technology Co., Ltd) and anti-TIM3 antibody (cat. no. 11872-1-AP; 1:1,000; Proteintech Group, Inc).

    Techniques: Western Blot, Expressing, Flow Cytometry, Fluorescence, Cell Culture, Control, Activation Assay

    Compound 053 enhances the in vivo antitumor effect of GEM in the 4T1 xenograft model. (A) Mouse treatment plan. (B) H&E staining of heart, liver, spleen, lung and kidney. Scale bar, 100 μ m. (C) Tumor morphology of mouse removed at 21 days of treatment. (D) The tumor size was measured with a caliper every 3 days and the volume was calculated (n=5). (E) Protein levels of CD3, CD4, CD8, 4-1BB, OX40, PD-1 and TIM3 were detected using immunohistochemical staining in tumor tissues of mice after 21 days of treatment. Nuclei are localized in blue and target proteins are localized in brown. Scale bar, 100 μ m. (F) Body weight was measured every 3 days (n=5). 053, FZU-0045-053; GEM, gemcitabine; 4-1BB, tumor necrosis factor receptor superfamily member 9; OX40, tumor necrosis factor receptor superfamily member 4; PD-1, programmed cell death protein 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3.

    Journal: International Journal of Oncology

    Article Title: Discovery of the late autophagy inhibitor FZU-0045-053 and its anti-breast cancer and immunomodulatory effects

    doi: 10.3892/ijo.2025.5823

    Figure Lengend Snippet: Compound 053 enhances the in vivo antitumor effect of GEM in the 4T1 xenograft model. (A) Mouse treatment plan. (B) H&E staining of heart, liver, spleen, lung and kidney. Scale bar, 100 μ m. (C) Tumor morphology of mouse removed at 21 days of treatment. (D) The tumor size was measured with a caliper every 3 days and the volume was calculated (n=5). (E) Protein levels of CD3, CD4, CD8, 4-1BB, OX40, PD-1 and TIM3 were detected using immunohistochemical staining in tumor tissues of mice after 21 days of treatment. Nuclei are localized in blue and target proteins are localized in brown. Scale bar, 100 μ m. (F) Body weight was measured every 3 days (n=5). 053, FZU-0045-053; GEM, gemcitabine; 4-1BB, tumor necrosis factor receptor superfamily member 9; OX40, tumor necrosis factor receptor superfamily member 4; PD-1, programmed cell death protein 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3.

    Article Snippet: The sections were then blocked with 5% BSA for 1 h at room temperature and subsequently incubated overnight at 4°C with the following primary antibodies: Anti-Ki67 antibody (cat. no. GB111499-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-LC3 antibody (cat. no. 81004-1-RR; 1:1,000; Proteintech Group, Inc), anti-p62 antibody (cat. no. GB11239-1-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-PD-L1 antibody (cat. no. GB150059-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-PD-L2 antibody (cat. no. 27406-1-AP; 1:4,000; Proteintech Group, Inc), anti-CD3 antibody (cat. no. GB11014-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-CD4 antibody (cat. no. GB11064-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-CD8 antibody (cat. no. GB11068; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-4-1BB/CD137 antibody (cat. no. A2025; 1:200; ABclonal Biotech Co., Ltd), anti-CD134/OX40 antibody (cat. no. 32621-1-AP; 1:500; Proteintech Group, Inc), anti-PD1 antibody (cat. no. GB153744-100; 1:400; Wuhan Servicebio Technology Co., Ltd) and anti-TIM3 antibody (cat. no. 11872-1-AP; 1:1,000; Proteintech Group, Inc).

    Techniques: In Vivo, Staining, Immunohistochemical staining

    Compound 053 modulates PD-L1 on tumor cells and co-stimulatory/co-inhibitory molecules on tumor-infiltrating T cells in the 4T1 xenograft model. (A) Flow cytometry was performed to analyze PD-L1 surface expression on tumor cells. The bar graph shows quantitative analysis of relative fluorescence intensity. (B) PD-1 expression on tumor-infiltrating T cells surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (C) TIM3 expression on tumor-infiltrating T cells surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (D) 4-1BB expression on tumor-infiltrating T cells surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (E) ICOS expression on tumor-infiltrating T cells surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (F) OX-40 expression on tumor-infiltrating T cells surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. Data are presented as mean ± SEM (n=3). Statistical significance was determined by one-way ANOVA followed by Dunnett's multiple comparisons test to compare all experimental groups against a single control group. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 vs. 0 μ M 053. (G) Flow cytometry was used to analyze the differentiation of CD3 + CD4 + T cells and CD3 + CD8 + T cells. 053, FZU-0045-053; 4-1BB, tumor necrosis factor receptor superfamily member 9; OX40, tumor necrosis factor receptor superfamily member 4; ICOS, inducible T-cell co-stimulator; PD-1, programmed cell death protein 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3; GEM, gemcitabine; PD-L1, programmed death-ligand 1.

    Journal: International Journal of Oncology

    Article Title: Discovery of the late autophagy inhibitor FZU-0045-053 and its anti-breast cancer and immunomodulatory effects

    doi: 10.3892/ijo.2025.5823

    Figure Lengend Snippet: Compound 053 modulates PD-L1 on tumor cells and co-stimulatory/co-inhibitory molecules on tumor-infiltrating T cells in the 4T1 xenograft model. (A) Flow cytometry was performed to analyze PD-L1 surface expression on tumor cells. The bar graph shows quantitative analysis of relative fluorescence intensity. (B) PD-1 expression on tumor-infiltrating T cells surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (C) TIM3 expression on tumor-infiltrating T cells surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (D) 4-1BB expression on tumor-infiltrating T cells surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (E) ICOS expression on tumor-infiltrating T cells surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. (F) OX-40 expression on tumor-infiltrating T cells surfaces was analyzed by flow cytometry. The bar graph shows quantitative analysis of relative fluorescence intensity. Data are presented as mean ± SEM (n=3). Statistical significance was determined by one-way ANOVA followed by Dunnett's multiple comparisons test to compare all experimental groups against a single control group. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 vs. 0 μ M 053. (G) Flow cytometry was used to analyze the differentiation of CD3 + CD4 + T cells and CD3 + CD8 + T cells. 053, FZU-0045-053; 4-1BB, tumor necrosis factor receptor superfamily member 9; OX40, tumor necrosis factor receptor superfamily member 4; ICOS, inducible T-cell co-stimulator; PD-1, programmed cell death protein 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3; GEM, gemcitabine; PD-L1, programmed death-ligand 1.

    Article Snippet: The sections were then blocked with 5% BSA for 1 h at room temperature and subsequently incubated overnight at 4°C with the following primary antibodies: Anti-Ki67 antibody (cat. no. GB111499-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-LC3 antibody (cat. no. 81004-1-RR; 1:1,000; Proteintech Group, Inc), anti-p62 antibody (cat. no. GB11239-1-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-PD-L1 antibody (cat. no. GB150059-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-PD-L2 antibody (cat. no. 27406-1-AP; 1:4,000; Proteintech Group, Inc), anti-CD3 antibody (cat. no. GB11014-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-CD4 antibody (cat. no. GB11064-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-CD8 antibody (cat. no. GB11068; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-4-1BB/CD137 antibody (cat. no. A2025; 1:200; ABclonal Biotech Co., Ltd), anti-CD134/OX40 antibody (cat. no. 32621-1-AP; 1:500; Proteintech Group, Inc), anti-PD1 antibody (cat. no. GB153744-100; 1:400; Wuhan Servicebio Technology Co., Ltd) and anti-TIM3 antibody (cat. no. 11872-1-AP; 1:1,000; Proteintech Group, Inc).

    Techniques: Flow Cytometry, Expressing, Fluorescence, Control

    Mechanism of compound 053 regulating autophagy and immune response to inhibit breast cancer. 053 can inhibit autophagy and promote apoptosis of breast cancer cells. 053 also downregulated PD-L1 expression in breast cancer cells, while promoting T cell activation and proliferation by upregulating co-stimulatory molecules (4-1BB, OX40 and ICOS) and downregulating co-inhibitory molecules (TIM-3 and PD-1) on the surface of the T cells. (By Figdraw). 4-1BB, tumor necrosis factor receptor superfamily member 9; OX40, tumor necrosis factor receptor superfamily member 4; ICOS, inducible T-cell co-stimulator; PD-1, programmed cell death protein 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3; PD-L1, programmed death-ligand 1.

    Journal: International Journal of Oncology

    Article Title: Discovery of the late autophagy inhibitor FZU-0045-053 and its anti-breast cancer and immunomodulatory effects

    doi: 10.3892/ijo.2025.5823

    Figure Lengend Snippet: Mechanism of compound 053 regulating autophagy and immune response to inhibit breast cancer. 053 can inhibit autophagy and promote apoptosis of breast cancer cells. 053 also downregulated PD-L1 expression in breast cancer cells, while promoting T cell activation and proliferation by upregulating co-stimulatory molecules (4-1BB, OX40 and ICOS) and downregulating co-inhibitory molecules (TIM-3 and PD-1) on the surface of the T cells. (By Figdraw). 4-1BB, tumor necrosis factor receptor superfamily member 9; OX40, tumor necrosis factor receptor superfamily member 4; ICOS, inducible T-cell co-stimulator; PD-1, programmed cell death protein 1; TIM3, T-cell immunoglobulin and mucin-domain containing-3; PD-L1, programmed death-ligand 1.

    Article Snippet: The sections were then blocked with 5% BSA for 1 h at room temperature and subsequently incubated overnight at 4°C with the following primary antibodies: Anti-Ki67 antibody (cat. no. GB111499-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-LC3 antibody (cat. no. 81004-1-RR; 1:1,000; Proteintech Group, Inc), anti-p62 antibody (cat. no. GB11239-1-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-PD-L1 antibody (cat. no. GB150059-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-PD-L2 antibody (cat. no. 27406-1-AP; 1:4,000; Proteintech Group, Inc), anti-CD3 antibody (cat. no. GB11014-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-CD4 antibody (cat. no. GB11064-100; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-CD8 antibody (cat. no. GB11068; 1:1,000; Wuhan Servicebio Technology Co., Ltd), anti-4-1BB/CD137 antibody (cat. no. A2025; 1:200; ABclonal Biotech Co., Ltd), anti-CD134/OX40 antibody (cat. no. 32621-1-AP; 1:500; Proteintech Group, Inc), anti-PD1 antibody (cat. no. GB153744-100; 1:400; Wuhan Servicebio Technology Co., Ltd) and anti-TIM3 antibody (cat. no. 11872-1-AP; 1:1,000; Proteintech Group, Inc).

    Techniques: Expressing, Activation Assay